Subscribe to the newsletterForward | Contact | www.lyonbiopole.com   January 2015
 
A LA UNE
01/28/2015 - Signature of the skills and training agreement LEEM / AFIPRAL / Lyonbiopole

Patrick Errard, President of LEEM, representing the Pharmaceutical Industries, Florence Agostino-Etchetto, Lyonbiopole's CEO and Pascal Reber, AFIPRAL President, Manufacturers Association of the Pharmaceutical Industry in the Rhône-Alpes Region signed an agreement on skills management and training to support the local indsutry and increasing employment and skills in health sector on Rhône-Alpes territory.
Contact: Valentine Lamort, GPEC and training assistant - valentine.lamort@lyonbiopole.com

01/12/2015 - Lyonbiopole, the first French health cluster to receive the Gold label

Lyonbiopole has received the European Gold label awarded by the "European Cluster Excellence Initiative" (ECEI). Already certified Bronze in 2012, alongside the 70 French competitiveness clusters, this award allows Lyonbiopole to distinguish by displaying now among the 47 most successful clusters in Europe in 9 countries. Supported by the European Commission (DG Enterprise and Industry) since 2010, the ECEI has evaluated European clusters on their level of performance and governance.
Contact: Emilie Romeo, European Projects Manager - emilie.romeo@lyonbiopole.com

Learn more


04/15-16/2015 - Registration opened for Investor Conference and Catalyzer of BIOVISION

Applications for BIOVISION Catalyzer and BIOVISION Investor Conference are opened since December 10th . Submission deadline: February 28th. BIOVISION Catalyzer allows start-ups and collaborative projects to gain visibility and partner search. BIOVISION Investor Conference provides an opportunity for companies seeking funding to pitch to a panel of investors.
Contact: Hugo Veysseyre, Clinical Innovation Project Manager - hugo.veysseyre@lyonbiopole.com

Learn more



ZOOM SUR
ImmunID

One month after receiving authorization from the French regulatory bodies for the PREDICT-ID study, ImmunID is delighted to announce that the first two clinical centers, in Lyon and Angers, have recruited five metastatic melanoma patients. "PREDICT-ID Melanoma" study is intended to assess the predictive value of immune profiles for response to Ipilimumab®, an immunomodulatory agent.  Bernhard Sixt , ImmunID’s Chairman commentes "The fast launch of the PREDICT-ID study is an indicator that ImmunTraCkeR® addresses a high unmet clinical need in the management of melanoma therapies.”

Learn more



A LA UNE
03/9-11/2015 - BIO Europe Spring Paris 2015

This event is considered as one of the major event of the biotechnology industry. It hosts over 2,000 participants, with no less than 11,000 appointments BtoB and over 1200 companies attending. Exhibitors are also expected to present the latest innovations in the sector. BIO- Europe Spring will bring together more than 40 countries around meetings, wokshops, business presentations. Discover the detailed program here. A special offer is available to our members who want to participate in this convention.
Contact: Simon Gudin, SMEs Development Project Manager  - 
simon.gudin@lyonbiopole.com

Learn more


06/15-18/2015 – Join the Rhône-Alpes delegation at BIO Philadelphia

Join Lyonbiopole's delegation for the next BIO international convention in Philadelphia (15 – 18th of June) and be part of the largest French delegation of Companies. Thanks to the support of the Rhône-Alpes regional council, and local administrations – Only Lyon, Grenobles Alps Metropole, and Lyon Chamber of Commerce, Lyonbiopole offers to its SMB members a tailor-made package for their participation to BIO Philadelphia 2015. Lyonbiopole's support includes financial support, broader visibility with the opportunity to be exhibitor on Lyonbiopole booth based on the French Pavilion and dedicated communication tools for the event. Visit us on the French Booth !
Contact: Simon Gudin, SMEs Development Project Manager - simon.gudin@lyonbiopole.com

Learn more



AGENDA
Bio Europe Spring 2015
From March, 9th to 11th, 2015 - Paris, France
2015 Annual Meeting of the HKS Inflammation and autoimmunity
From April 14th to 16th, 2015 - Annecy, France
Biovision 2015
From April 15th to 16th, 2015 - Lyon, France
BIO International Convention 2015
From June 15th to 17th 2015 - Philadelphie, US
Casym summer school
From June 22th to 26th, 2015 - Stockholm, Swedeen
5th edition of ICCR Congress
From July 8th to 12th, 2015 - Quebec, Canada
 
A LA UNE
01/2015 - Eurostars: call for projects open


Eurostars call for projects is open. This funding programme is fully dedicated to innovative SMEs aiming to launch R&D projects closed to the market, that are collaborative and European (at least 2 partners from EU). The funding rate for projects goes from 30 to 40% (subsidy managed by BPI France). The submission deadline is fixed on 03/5/2015. Lyonbiopole supports you to build up European projects.
Contact: Emilie Romeo, European Projects Manager - emilie.romeo@lyonbiopole.com

Learn more


12/2014 - EDCTP2 launches its new calls for projects

The EDCTP initiative "European & Developping Countries Clinical Trials Partnerships" launches new calls for projects. This program aims to support the development of clinical trials between some European and African countries and third parties such as the Bill and Melinda Gates Foundation. Three families of calls can be financed: clinical trials, research grants and capacity building mainly for the fight against HIV / AIDS, malaria and tuberculosis. EDCTP2 includes infectious neglected diseases, all clinical phases will be possible and the diagnostic approach is integrated. A first call within the family "clinical trials" is launched the development of diagnostic tools for infectious diseases linked to poverty. Deadline : 03/02/2015.
Contact: Emilie Romeo, European Projects Manager - emilie.romeo@lyonbiopole.com

Learn more


11/2012 - H2020 SME instrument

H2020 program includes the SME instrument. It targets the highly innovative SMEs with a strong ambition to develop, grow and internationalize; focusing on the delivery of new products, services or processes on the market. For SMEs in the health sector, the SME instrument is focused on the PHC-12 Clinical research for the validation of biomarkers and/or diagnostic medical devices line. The project can be presented by a single SME, and different phases depending on the maturity of the project. Next submission deadline: Phase 1 & 2 projects = 03/18/2015. Lyonbiopole supports you to build up European projects.
Contact: Emilie Romeo, European Projects Manager - emilie.romeo@lyonbiopole.com

12/2014 – IMI 2: calls for projects open



IMI (Innovative Medicines Initiative) is a public-private partnership between the pharmaceutical groups, members of EFPIA and the European Union. Its aim is to financially support collaboration in the field of innovative medicines in order to increase security and efficiency. As part of IMI 2, 2 calls have just been launched: Call 3 (deadline on 03/24/2014) and Call 4 (deadline 02/11/2015). Find the call details here and the next dates of webinars. Lyonbiopole supports you to build up European projects.
Contact: Emilie Romeo, European Projects Manager - emilie.romeo@lyonbiopole.com

Learn more


01/2015 –  Several transnational ERA-NET calls open


Several ERA-NET calls on the Health theme are open, such as the 6th ERA-NET II EuroNanoMed call on nanomedicine, 3rd INFECT-ERA call on Infectious Diseases, 7th ERA-NET call Cofund-3 E-Rare on rare diseases. These programs aim to finance transnational collaborative research projects (involving academic / SMEs). In general, projects should gather at least 3 partners from 3 countries participating in the ERA-NET. The French teams are funded by the ANR. Find details of the calls on the ANR website.
Contact: Emilie Romeo - European Projects Manager - emilie.romeo@lyonbiopole.com

Learn more


01/2015 – New call H2020 - Fast track to innovation


The European Commission launches a new initiative Fast Track to Innovation (FTI) under H2020. It aims to give to innovative companies a final push before the access to market. The projects must focus on industrial development. Consortia should bring 3-5 organizations (mostly companies). All fields of technology are concerned. Several submission dates are planned in 2015 (next deadline 04/29/2015).
Contact: Emilie Romeo - European Projects Manager - emilie.romeo@lyonbiopole.com

Learn more



A LA UNE
01/20/2015 - Adocia initiates a clinical study on the post-meal effect of ultrarapid BioChaperone Lispro insulin formulation

The study aims to measure the effect of BioChaperone Lispro, injected at the time of a standardized meal, on post-meal glycemic control in type 1 diabetes patients and compare this effect to that of Humalog® (insulin lispro rDNA origin).

Learn more


01/12/2015 - Erytech announces ADR level 1 Listing in the US

ERYTECH, the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, today announced the launch of a sponsored American Depository Receipt (ADR) Level 1 listing in the United States in order to support the expansion of the Company’s US investor base.

Learn more


01/12/2015 - Valneva announces the launch of a capital increase

Following its announcement on January 5th, European biotechnology company Valneva announced the launch of a capital increase with preferential subscription rights for holders of ordinary shares for a gross amount of approximately EUR 45 million (the “Rights Issue”). This Rights Issue is part of the financing for the acquisition of Crucell Sweden AB and all assets, licenses and privileges related to Dukoral®1, a vaccine against cholera and traveler’s diarrhea caused by ETEC (Enterotoxigenic Escherichia coli), as well as a Nordics vaccine  distribution business of the seller and its affiliates (the “Acquisition”). The net proceeds of the Rights Issue are estimated to amount to approximately EUR 42 million.

Learn more

 
© Lyonbiopole 2019  |  CREDITS  |  LEGAL NOTICE  |